(Q54522094)

30 May 2018

title

Clinical and histopathologic characteristics of rash in cancer patients treated with mammalian target of rapamycin inhibitors. (English)

1 reference

30 May 2018

1 reference

6

1 reference

30 May 2018

Jason Konner

8

1 reference

30 May 2018

Mario E Lacouture

11

1 reference

30 May 2018

Darren R Feldman

object named as

Darren R Feldman

7

0 references

author name string

Yevgeniy Balagula

1

1 reference

30 May 2018

Alyx Rosen

2

1 reference

30 May 2018

Belinda H Tan

3

1 reference

30 May 2018

Klaus J Busam

4

1 reference

30 May 2018

Melissa P Pulitzer

5

1 reference

30 May 2018

Diane Reidy-Lagunes

9

1 reference

30 May 2018

Patricia L Myskowski

10

1 reference

30 May 2018

language of work or name

English

0 references

publication date

21 March 2012

1 reference

30 May 2018

number of pages

6

1 reference

based on heuristic

inferred from page(s)

published in

Cancer

1 reference

30 May 2018

volume

118

1 reference

30 May 2018

issue

20

1 reference

30 May 2018

page(s)

5078-5083

1 reference

30 May 2018

mTOR signaling and drug development in cancer

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27505

The emerging safety profile of mTOR inhibitors, a novel class of anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27505

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27505

The risk of skin rash and stomatitis with the mammalian target of rapamycin inhibitor temsirolimus: a systematic review of the literature and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27505

mTOR inhibitor-associated dermatologic and mucosal problems

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27505

Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27505

Phase 1/2 study of everolimus in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27505

Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27505

Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27505

The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27505

Cutaneous adverse events in renal transplant recipients receiving sirolimus-based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27505

Eosinophilic rash secondary to temsirolimus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27505

Involvement of the Akt/mTOR pathway on EGF-induced cell transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27505

A keratin cytoskeletal protein regulates protein synthesis and epithelial cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27505

Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27505

Acne in recipients of renal transplantation treated with sirolimus: clinical, microbiologic, histologic, therapeutic, and pathogenic aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27505

inferred from DOI database lookup

7 January 2021

based on heuristic

Skin rash secondary to bevacizumab in a patient with advanced colorectal cancer and relation to response

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27505

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1002/CNCR.27505

1 reference

30 May 2018

1 reference

30 May 2018